Why Amarin stock is rallying today
Amarin Corporation (NASDAQ: AMRN) shares got a major boost during the pre-market hours of Thursday after it said the American...
Health Care
Arcadia Biosciences stock down despite solid Q4 results
Arcadia Biosciences (RKDA) stock decreased by nearly 2% in the extended hours of trading despite the fourth quarter results surpassed...
Earnings preview: What’s on the cards for Biocept in Q4
Biocept (BIOC) is scheduled to report fourth quarter and full year 2018 results on March 28, Thursday, after the regular...
Catalyst Pharmaceuticals stock soars to 12-year high
Catalyst Pharmaceuticals Inc. (CPRX) stock surged to a 12-year high of $5.59 on Wednesday. Investors were positive about the prospect...
Earnings: Affimed cuts down losses in 2018
Affimed N.V. (AFMD), a clinical stage biopharmaceutical company that focuses on oncology drugs, Wednesday reported net losses that narrowed in...
Fennec Pharma stock plunges to all-time low
Fennec Pharmaceuticals Inc. (FENC) stock plunged to an all-time low of $4.69 on Tuesday. Investors were concerned about the future...
Aldeyra Therapeutics stock resumes trading, surges about 60% on positive trial results
After getting halted in Nasdaq for sometime, shares of Aldeyra Therapeutics (ALDX) resumed trading and climbed up about 60% during...
Onconova Therapeutics cuts down losses in 2018
Onconova Therapeutics (ONTX), a Phase 3 biopharmaceutical company that focuses on developing cancer drugs, Tuesday posted a narrowed loss in...
Earnings Preview: Aeterna Zentaris reporting Q4 results on Mar 26
Aeterna Zentaris (AEZS) is scheduled to report its fourth-quarter financial results on March 26, Tuesday, after the regular trading hours....
Canopy Growth accelerates US expansion plans with AgriNextUSA acquisition
The world’s largest cannabis company by market cap, Canopy Growth Corporation (CGC), on Thursday said it was acquiring US-based hemp...
What is NASH and which biotech firms are vying for the first-mover status
NASH, or Nonalcoholic steatohepatitis, is undeniably a golden goose in the pharma space. The biggest corporate attraction towards this liver...
Aurinia’s loss widened to $14.6 million in Q4 2018
Aurinia Pharmaceuticals (NASDAQ: AUPH/TSX: AUP) reported its fourth quarter and full-year 2018 results after the bell today. The company reported...
Catalyst Pharma loss widens in Q4 due to Firdapse launch
Catalyst Pharmaceuticals (Nasdaq: CPRX) reported a loss of $0.14 per share compared to $0.12 loss expected by the street. The...
Dermira stock doubles and hits new 52-week high on positive eczema trial results
Dermira Inc. (DERM) announced positive results from Phase 2b study for treating patients with atopic dermatitis, a condition which causes...
Axsome Therapeutics stock climbs to 34-month high
After the slump on weak quarterly results, investors turned positive on Axsome Therapeutics (AXSM) stock, which climbed to the 34-month...
NASH drug developer Genfit plans $132-million US IPO, to list on Nasdaq
France-based biopharmaceutical firm Genfit (EPA: GNFT) has launched a global offering of its American Depository Shares and ordinary shares to...
Novavax misses Q4 estimates, shares slip
NVAX Earnings Transcripts NVAX Earnings Calendar Clinical-stage vaccine company Novavax (NVAX) reported a loss of 13 per share in...
Earnings Preview: Aurinia’s Q4 results pivot on AURORA trial updates
Shares of Aurinia Pharmaceuticals (NASDAQ: AUPH/TSX: AUP) rose 13% on February 25 when the US patent office extended the patent...
Earnings preview Q4: Amyris likely to benefit from the new cannabinoid deal
Renewables product company Amyris (AMRS) is set to report its fourth quarter and full-year 2018 results on Monday, March 18...
Latest FDA approval sends Arcadia Biosciences 23% higher
Shares of Arcadia Biosciences (RKDA) popped 23% during pre-market trading on Friday, after it received approval from the US Food...
Tilray (TLRY) Q4 earnings preview: All you need to know
Tilray (TLRY), which has been trailing other cannabis stocks since the start of this year, will be put under the...